A
0.295
0.06 (25.53%)
| Previous Close | 0.235 |
| Open | 0.245 |
| Volume | 14,439,048 |
| Avg. Volume (3M) | 5,276,247 |
| Market Cap | 114,446,128 |
| Price / Book | 5.27 |
| 52 Weeks Range | |
| Earnings Date | 30 May 2025 |
| Profit Margin | -173.69% |
| Operating Margin (TTM) | -166.12% |
| Diluted EPS (TTM) | -0.020 |
| Quarterly Revenue Growth (YOY) | 18.60% |
| Total Debt/Equity (MRQ) | 0.07% |
| Current Ratio (MRQ) | 7.91 |
| Operating Cash Flow (TTM) | -6.89 M |
| Levered Free Cash Flow (TTM) | -4.77 M |
| Return on Assets (TTM) | -22.47% |
| Return on Equity (TTM) | -40.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | AMPLIA FPO [ATX] | - | - |
AIStockmoo Score
0.3
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.25 |
|
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 20.00% |
| % Held by Institutions | 19.30% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |